BioAge Labs

We are thrilled to announce the closing of BioAge's IPO! As of September 26, we are trading on Nasdaq as $BIOA. This milestone will enable our development of novel therapies that treat metabolic diseases by harnessing the biology of aging. Heartfelt thanks to the BioAge team for their brilliance and dedication, and to the investors and partners who believed in our vision and supported us on our journey. Together, they made this day possible. As we look to the future, we will continue to advance innovative treatments for the most prevalent and pressing health challenges of our time. Here’s to the next chapter, and to longer, healthier lives for all! Details: https://lnkd.in/g9kyj6xT

We’re honored that BioAge CEO & co-founder Kristen Fortney is being recognized as one of the most exceptional entrepreneurs of 2024 at Goldman Sachs Builders and Innovators Summit, a gathering of founders and CEOs of high-growth companies taking place in Healdsburg, California. “I am thrilled to recognize Dr. Kristen Fortney as one of the most exceptional entrepreneurs of 2024,” said David Solomon, Chairman and CEO of Goldman Sachs. “Kristen and her team have built an impressive business that continues to grow at scale. We look forward to bringing this year’s cohort together to share insights on topics ranging from the evolving geopolitical landscape and accessing new pools of capital to using the power of storytelling to reach new audiences.” Excited to see the ideas starting with #GSInnovators, and looking forward to hearing from leading entrepreneurs and thought leaders at this event!

?? BioAge CEO & co-founder Kristen Fortney has been recognized as a “Cardiometabolic All-Star” in the 2024 PharmaVoice 100, a list that salutes biotech leaders who are leading in transformational times for the industry and forging new paths for others to follow. “Fortney’s breakthrough insight — that the mechanisms governing aging are linked to the pathogenesis of age-related diseases —?fits neatly into the wider goals of obesity drug development, and could lead to therapies that restore body composition and boost metabolism overall.” https://lnkd.in/dQzracmz

The BioAge podcast, Translating Aging, features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan. Our newest episode just dropped!

On Wednesday September 25th, BioAge’s VP-Translational Aging Biology Yan Wang will speak at Biocytogen’s Bay Area forum on “Robust In Vivo Models: De-Risking Clinical Trials.” In her talk, Yan will share how our translational in vivo studies catalyzed the clinical development of our lead product candidate, the APJ agonist azelaprag, currently in a Phase 2 clinical trial for obesity. Register for this in-person event here: https://lnkd.in/g9Ccypns

Tonight at the Aging Research & Drug Discovery Meeting , BioAge CBO & Head of Brain Aging Peng Leong joined a panel of luminaries to discuss the dense connections between early-stage development in longevity biotech and the broader pharma sector. Their wide-ranging conversation encompassed the concepts at the very foundation of longevity biotech, the challenges of translating geroscience into the clinic, and how they envision the future of drug discovery and development at the intersection of aging biology and disease. ??What are the optimal indications for clinical trials? ??How do earlier-stage biotechs get to know potential pharma partners? ??What is pharma looking for in the biotech startups they partner with? ??Where are the opportunities to be grasped - and the pitfalls to be avoided? Many thanks to amazing moderator Michael Ringel of Boston Consulting Group (BCG) for his thoughtful and incisive questions, and to the stellar panelists - David Glass (Regeneron), Johan Luthman (Lundbeck), Jonathan Wilson (Eli Lilly and Company), and Alex Zhavoronkov (Insilico Medicine) - for a fascinating discussion!

Action shot! Naisha S., BioAge's VP-Data Science, giving her talk entitled "Targeting aging biology: exercise induced pathways for the treatment of metabolic disease" on the main stage at the Aging Research & Drug Discovery Meeting in Copenhagen.

At the Aging Research & Drug Discovery Meeting in Copenhagen today, our VP of Data Science Naisha S. gave a talk on drug target discovery for metabolic disease?at the intersection of exercise and aging. Her presentation showcased how how BioAge analyzes human longevity data to identify exercise-induced pathways, underpinning our mission to develop therapies for metabolic diseases.

We are delighted to welcome Sangita Ghosh, PhD as BioAge's new Senior Vice President of Chemistry, Manufacturing, and Controls (CMC). With over two decades of experience in pharmaceutical development and a track record of bringing multiple drugs to market, Dr. Ghosh will be instrumental as we progress our lead candidate, azelaprag, through clinical trials. Great to have you on the team, Sangita!